Company profile: Olink
1.1 - Company Overview
Company description
- Provider of proteomics platforms and services for biomolecular analysis, including Olink Explore for high-throughput protein biomarker discovery (3072 assays, minimal sample volume), Olink Target 96/48 qPCR panels for disease- or biology-focused studies, Olink Flex customizable panels (up to 21 human proteins), the Olink Signature benchtop readout instrument, and Olink Analysis Service for Target and Explore.
Products and services
- Olink Analysis Service: End-to-end service where Olink experts run client sample analyses across Olink Target 96/48 and Olink Explore platforms for protein biomarker discovery and targeted, disease- or biology-focused studies
- Olink Explore: High-throughput platform enabling protein biomarker discovery, measuring 3072 assays with minimal sample volume
- Olink Target 96/48: qPCR-based panels for targeted protein biomarker analysis, offering 96-plex or 48-plex readouts tailored to disease- or biology-focused studies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Olink
Alamar Biosciences
HQ: United States
Website
- Description: Provider of technologies enabling the earliest possible detection and treatment of cancer and other diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alamar Biosciences company profile →
Phasefocus
HQ: United Kingdom
Website
- Description: Provider of Virtual Lens and ptychographic imaging technologies that generate high-definition amplitude and phase images without high-quality lenses for optical, X-ray and electron microscopy. Products include Livecyte, a label-free system to track and analyze live cell behavior, and πBox, a ptychographic reconstruction engine for electron microscopy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phasefocus company profile →
Amaryllis Nucleics
HQ: United States
Website
- Description: Provider of proprietary RNA sequencing methods and end-to-end solutions delivering shorter turnaround from RNA to library prep and complete data analysis at a lower cost per sample compared to whole transcriptome sequencing approaches for RNASeq; Bay Area-based start-up.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amaryllis Nucleics company profile →
BioLife Solutions
HQ: United States
Website
- Description: Provider of cryopreservation media, hypothermic storage/shipping solutions, automated thawing systems, temperature-controlled biostorage services, and human platelet lysates for cell culture. Products include CryoStor (-70 to -196°C freeze media), HypoThermosol (2–8°C, serum/protein-free), ThawSTAR (water-free, standardized thawing), SciSafe Storage Solutions, Stemulate (xeno/heparin-free), and nLiven PR (GMP-ready, pathogen-reduced).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioLife Solutions company profile →
Syndesi Therapeutics
HQ: Belgium
Website
- Description: Provider of drug candidates and molecules that uniquely modulate the synaptic vesicle protein SV2A to regulate synaptic transmission, representing a promising approach to treating Alzheimer’s disease and other neurological disorders with cognitive impairment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Syndesi Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Olink
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Olink
2.2 - Growth funds investing in similar companies to Olink
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Olink
4.2 - Public trading comparable groups for Olink
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →